JP2011505386A - 白血病性幹細胞の阻害方法 - Google Patents

白血病性幹細胞の阻害方法 Download PDF

Info

Publication number
JP2011505386A
JP2011505386A JP2010536288A JP2010536288A JP2011505386A JP 2011505386 A JP2011505386 A JP 2011505386A JP 2010536288 A JP2010536288 A JP 2010536288A JP 2010536288 A JP2010536288 A JP 2010536288A JP 2011505386 A JP2011505386 A JP 2011505386A
Authority
JP
Japan
Prior art keywords
cells
aml
region
antibody
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2010536288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011505386A5 (OSRAM
Inventor
ジョン エドガー ディック
リキング ジン
ジーノ ルイジ ヴァイロ
デイヴィット ポール ギアリング
サマンサ ジェーン バスフィールド
Original Assignee
シーエスエル、リミテッド
ユニヴァーシティ ヘルス ネットワーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーエスエル、リミテッド, ユニヴァーシティ ヘルス ネットワーク filed Critical シーエスエル、リミテッド
Publication of JP2011505386A publication Critical patent/JP2011505386A/ja
Publication of JP2011505386A5 publication Critical patent/JP2011505386A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010536288A 2007-12-06 2008-12-04 白血病性幹細胞の阻害方法 Abandoned JP2011505386A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99681907P 2007-12-06 2007-12-06
PCT/AU2008/001797 WO2009070844A1 (en) 2007-12-06 2008-12-04 Method of inhibition of leukemic stem cells

Publications (2)

Publication Number Publication Date
JP2011505386A true JP2011505386A (ja) 2011-02-24
JP2011505386A5 JP2011505386A5 (OSRAM) 2011-12-01

Family

ID=40717202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010536288A Abandoned JP2011505386A (ja) 2007-12-06 2008-12-04 白血病性幹細胞の阻害方法

Country Status (13)

Country Link
US (6) US20110052574A1 (OSRAM)
EP (1) EP2231187A4 (OSRAM)
JP (1) JP2011505386A (OSRAM)
KR (1) KR20100094527A (OSRAM)
CN (1) CN101896200A (OSRAM)
AU (1) AU2008331436A1 (OSRAM)
BR (1) BRPI0819887A2 (OSRAM)
CA (1) CA2706337A1 (OSRAM)
EA (1) EA201070687A1 (OSRAM)
IL (1) IL205951A0 (OSRAM)
MX (1) MX2010006213A (OSRAM)
WO (1) WO2009070844A1 (OSRAM)
ZA (1) ZA201003515B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524296A (ja) * 2015-06-12 2018-08-30 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１２３抗体及びその複合体

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209341A1 (en) * 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
JP5694923B2 (ja) * 2009-04-27 2015-04-01 協和発酵キリン株式会社 血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法
EP2332994A1 (en) * 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
AU2011217728B2 (en) * 2010-02-17 2013-03-14 Csl Limited Compositions and methods for targeting type 1 interferon producing cells
AU2013200910B2 (en) * 2010-02-17 2015-06-11 Csl Limited Composition and methods for targeting type 1 interferon producing cells
KR20130032866A (ko) * 2010-02-18 2013-04-02 더 유니버시티 오브 멜버른 만성 염증 상태의 치료
WO2011156860A1 (en) 2010-06-15 2011-12-22 Csl Limited IMMUNOTHERAPEUTIC METHOD INVOLVING CD123 (IL-3Rα) ANTIBODIES AND IMMUNOSTIMULATING COMPLEX
NZ604510A (en) * 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
AU2011253598B1 (en) * 2010-08-17 2012-01-19 Csl Limited Humanized anti-interleukin 3 receptor alpha chain antibodies
AU2012202125B2 (en) * 2010-08-17 2015-03-19 Csl Limited Humanized Anti-Interleukin 3 Receptor Alpha Chain Antibodies
MX365321B (es) * 2012-06-07 2019-05-29 Los Angeles Childrens Hospital Métodos para el tratamiento de neutropenia mediante agonistas retinoides.
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
WO2014138805A1 (en) * 2013-03-14 2014-09-18 Csl Limited Anti il-3r alpha agents and uses thereof
CN103740639A (zh) * 2013-09-02 2014-04-23 北京大学人民医院 构建人源化Ph染色体阳性急性淋巴细胞白血病小鼠模型的方法
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20160111672A (ko) * 2015-03-17 2016-09-27 한밭대학교 산학협력단 규칙적으로 배열된 미세 부호를 포함하는 인쇄물에 대한 구동 시스템，방법 및 그 제작 방법
US9969807B2 (en) * 2015-04-08 2018-05-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD123
AU2016282723B2 (en) 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN108350077A (zh) * 2015-11-03 2018-07-31 糖模拟物有限公司 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017216028A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CN107840889A (zh) * 2016-09-19 2018-03-27 上海吉倍生物技术有限公司 高亲和力的抗cd123抗体及其应用
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
CA3047491A1 (en) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs of cytotoxic active agents having enzymatically cleavable groups
KR102556826B1 (ko) 2016-12-21 2023-07-18 바이엘 파마 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 항체 약물 접합체 (adc)
WO2019149637A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN112042597B (zh) * 2020-07-22 2022-04-29 南京普恩瑞生物科技有限公司 一种双人源化肿瘤异种移植模型的构建方法
CN111920802B (zh) * 2020-09-11 2024-01-23 华侨大学 穿心莲内酯在制备防治成人t细胞白血病药物的应用
AU2021414400A1 (en) 2020-12-31 2023-08-17 Innate Pharma Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123
CN119365495A (zh) 2022-05-27 2025-01-24 赛诺菲 与NKp46和BCMA变体结合的具有Fc工程化的自然杀伤（NK）细胞接合物
EP4619044A1 (en) 2022-11-17 2025-09-24 Hans-Georg Lerchen Antibody-drug-conjugates cleavable in a tumor microenvironment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177078B1 (en) * 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008127735A1 (en) * 2007-04-13 2008-10-23 Stemline Therapeutics, Inc. Il3ralpha antibody conjugates and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177078B1 (en) * 1995-12-29 2001-01-23 Medvet Science Pty Limited Monoclonal antibody antagonists to IL-3
JP2004509835A (ja) * 2000-03-06 2004-04-02 ユニヴァーシティ　オブ　ケンタッキー　リサーチ　ファンデーション 血液癌前駆細胞を障害する方法およびその関連化合物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN6013020558; メルクマニュアル　第１８版　日本語版 , 20070425, ｐ．１２２７-１２３０, 日経ＢＰ社 *
JPN6013030704; Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｉｃａｌ　Ｍｅｔｈｏｄｓ Ｖｏｌ．３０６，　Ｎｏ．１-２, 2005, ｐ．１５１-１６０ *
JPN6013030706; Ｂｉｏｔｈｅｒａｐｙ 第１７巻，第５号, 200309, ｐ．４１５-４２１ *
JPN6013030708; Ｔｒｅｎｄｓ　ｉｎ　Ｇｌｙｃｏｓｃｉｅｎｃｅ　ａｎｄ　Ｇｌｙｃｏｔｅｃｈｎｏｌｏｇｙ 第１８巻，第１００号, 200603, ｐ．１２９-１３６ *
JPN6013030710; Ｂｌｏｏｄ Ｖｏｌ．８７，　Ｎｏ．１, 19960101, ｐ．８３-９２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524296A (ja) * 2015-06-12 2018-08-30 シアトル ジェネティクス，インコーポレーテッド Ｃｄ１２３抗体及びその複合体
JP2021000130A (ja) * 2015-06-12 2021-01-07 シアトル ジェネティクス インコーポレーテッド Ｃｄ１２３抗体及びその複合体

Also Published As

Publication number Publication date
ZA201003515B (en) 2011-08-31
US20200207861A1 (en) 2020-07-02
WO2009070844A1 (en) 2009-06-11
EP2231187A1 (en) 2010-09-29
AU2008331436A1 (en) 2009-06-11
US20170029515A1 (en) 2017-02-02
US20110052574A1 (en) 2011-03-03
CN101896200A (zh) 2010-11-24
BRPI0819887A2 (pt) 2017-05-23
IL205951A0 (en) 2010-11-30
CA2706337A1 (en) 2009-06-11
MX2010006213A (es) 2010-09-07
EA201070687A1 (ru) 2010-12-30
EP2231187A4 (en) 2013-02-20
US20180079818A1 (en) 2018-03-22
KR20100094527A (ko) 2010-08-26
US20130230510A1 (en) 2013-09-05
US20150152185A1 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
US20200207861A1 (en) Method of inhibition of leukemic stem cells
CN111836830B (zh) Cd70组合疗法
JP2021118719A (ja) Ｔｉｇｉｔ結合物質およびその使用法
KR20150076178A (ko) T 세포 인게이저로서 이중특이적 IgG 항체
JP2022538733A (ja) 新規抗ｃｄ２５抗体
JP2022533253A (ja) ｃ－ｋｉｔ及びＣＤ４７に対する免疫療法剤の同時投与レジメン
MX2014006207A (es) Terapia de combinacion de un anticuerpo anti-cd20 e il-15 humano de citocina.
AU2011267837B2 (en) Immunotherapeutic method involving CD123 (IL-3Ralpha) antibodies and immunostimulating complex
US20220288118A1 (en) Depletion regimes for engineered t-cell or nk-cell therapy
US20240368288A1 (en) Bispecific anti-flt3/cd3 antibodies and methods of use
CN118284621A (zh) 抗flt3抗体、car、car t细胞和使用方法
US20240216432A1 (en) Anti-flt3 antibodies, cars, car t cells and methods of use
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
WO2022214681A1 (en) Methods for the treatment of anaplastic large cell lymphoma
HK40095839A (en) Cd70 combination therapy
HK40033769A (en) Cd70 combination therapy
HK40031662A (en) Cd70 combination therapy
HK40031662B (en) Cd70 combination therapy
OA16352A (en) CD33 binding agents.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111012

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20121217

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20130327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130626

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131120